After 35 years of tireless work, the Multidisciplinary Association for Psychedelic Studies (MAPS) is knocking down the door of FDA approval for MDMA-assisted psychotherapy for PTSD.
The Phase 3 trial results have been nothing short of astounding, and having this modality as an FDA-approved treatment will vastly improve the lives of so many who have been struggling with PTSD for too long.
But how will this affect your medical practice, and how can your patients get this life-changing therapy?
To answer those questions, we are honored to have four members of the MAPS team on this month’s panel to cover:
• Results of the Phase 3 trials
• Clinical practice guidelines regarding MDMA-assisted psychotherapy
• How this modality may look post-FDA approval
As always, there will be ample time for audience Q & A, so you’ll get to interact with the panelists directly!
So please join us for this live panel discussion on Thursday, June 24th at 5 pm Pacific, 8 pm Eastern. This is exclusively for members of the Psychedelic Medicine Association, so if you have not yet registered, please do so here. And for members, please register for the panel here. A link to the recording will be available afterwards if you cannot make it to the live event.
Hope to see you all on the 24th!


